This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Search results
From Proteopedia
You searched for Venetoclax
There is no page with the exact title "Venetoclax". The search results for "Venetoclax" are displayed below. You can create a page titled Venetoclax (by clicking on the red link).
For more information about searching Proteopedia, see Help.
To exclude pages titled with 4-character PDB codes, use the checkbox "only Human created pages" at the bottom of this page.
Showing below up to 20 results starting with #1.
View (previous 20) (next 20) (20 | 50 | 100 | 250 | 500)
Article title matches
- Category:Venetoclax (41 bytes)
1: List of pages with the keyword Venetoclax
Page text matches
- 8ekx (5,093 bytes)
14: ...of ABBV-467 as monotherapy or in combination with venetoclax inhibits the growth of xenografts from human hema... - 8htr (3,520 bytes)
12: ...101V) have been reported to mediate resistance to venetoclax after long-term treatment. Herein, we described n... - 8hts (3,547 bytes)
12: ...101V) have been reported to mediate resistance to venetoclax after long-term treatment. Herein, we described n... - 6fs0 (3,861 bytes)
15: ... monotherapy or in combination with bortezomib or venetoclax. Based on these promising data, a Phase I clinica... - 6fs1 (4,088 bytes)
14: ... monotherapy or in combination with bortezomib or venetoclax. Based on these promising data, a Phase I clinica... - 6fs2 (3,962 bytes)
14: ... monotherapy or in combination with bortezomib or venetoclax. Based on these promising data, a Phase I clinica... - 6gva (7,739 bytes)
16: ... as a combination therapy with the BCL2-targeting venetoclax. These findings support further studies of combin... - 6o0k (4,983 bytes)
2: ==crystal structure of BCL-2 with venetoclax==
16: ...provides a framework for considering analogues of venetoclax that might be effective in combating this mutatio...
18: Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutation... - 6o0l (4,954 bytes)
2: ==crystal structure of BCL-2 G101V mutation with venetoclax==
16: ...provides a framework for considering analogues of venetoclax that might be effective in combating this mutatio...
18: Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutation... - 6o0m (5,000 bytes)
2: ==crystal structure of BCL-2 F104L mutation with venetoclax==
16: ...provides a framework for considering analogues of venetoclax that might be effective in combating this mutatio...
18: Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutation... - 6o0o (4,922 bytes)
16: ...provides a framework for considering analogues of venetoclax that might be effective in combating this mutatio...
18: Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutation... - 6o0p (4,999 bytes)
2: ==crystal structure of BCL-2 G101A mutation with venetoclax==
16: ...provides a framework for considering analogues of venetoclax that might be effective in combating this mutatio...
18: Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutation... - Category:Venetoclax (41 bytes)
1: List of pages with the keyword Venetoclax - 6uvc (4,285 bytes)
14: ...tered the clinic and the BCL-2 inhibitor, ABT-199/venetoclax, is already proving transformative. For BCL-XL, n... - 6uvd (4,210 bytes)
14: ...tered the clinic and the BCL-2 inhibitor, ABT-199/venetoclax, is already proving transformative. For BCL-XL, n... - 6uve (4,144 bytes)
14: ...tered the clinic and the BCL-2 inhibitor, ABT-199/venetoclax, is already proving transformative. For BCL-XL, n... - 6uvf (4,178 bytes)
14: ...tered the clinic and the BCL-2 inhibitor, ABT-199/venetoclax, is already proving transformative. For BCL-XL, n... - 6uvg (4,207 bytes)
14: ...tered the clinic and the BCL-2 inhibitor, ABT-199/venetoclax, is already proving transformative. For BCL-XL, n... - 6uvh (4,292 bytes)
14: ...tered the clinic and the BCL-2 inhibitor, ABT-199/venetoclax, is already proving transformative. For BCL-XL, n... - 6vo4 (3,524 bytes)
13: ...ains an undrugged oncogenic protein and can cause venetoclax resistance. Having identified a unique C55 residu...
View (previous 20) (next 20) (20 | 50 | 100 | 250 | 500)
You may also try
